Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Suprachoroidal drug delivery is a recent route for managing various ocular conditions. Safety and long term results are still under investigations.
In this study, we aim to analyze the long term results of suprachoroidal injection in treating various retinal diseases to focus on its efficacy, safety and long term ocular effects as ocular hypertension, cataract progression and macular edema resolution.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Diabetic macular edema | Active Comparator | Cases with diabetic macular edema with central macular thickness more than 300 microns measured by optical coherence tomography. |
|
| Vogt-koyanagi harada | Active Comparator | Cases with vogt-koyanagi harada and complicated with exudative retinal detachment confirmed by optical coherence tomography. |
|
| Retinal vein occlusion | Active Comparator | Cases with retinal vein occlusion and complicated with macular edema confirmed by optical coherence tomography. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Suprachoroidal triamcinolone acetonide injection | Drug | Pars plana suprachoroidal injection of 4mg//0.1ml triamcinolone acetonide. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Visual acuity | Changes noted in vision after injection measured 8n logMar units by snellen chart. | Baseline and up to one year after injection. |
| Measure | Description | Time Frame |
|---|---|---|
| Central macular thickness | Changes noted in central macular thickness after injection measured by optical coherence tomography in microns. | Baseline and up to one year after injection. |
| Measure | Description | Time Frame |
|---|---|---|
| Intraocular pressure | Changes noted in intraocular pressure after injection measured by applanation tonometry in millimeter mercury. | Baseline and up to one year after injection. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Ahmed A Tabl | Contact | 01222328766 | ahmad4lg@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Ahmed A Tabl | Benha University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ahmed Abdelshafy Tabl | Recruiting | Banhā | Benha | 13511 | Egypt |
Not provided
| ID | Term |
|---|---|
| D014607 | Uveomeningoencephalitic Syndrome |
| D012170 | Retinal Vein Occlusion |
| ID | Term |
|---|---|
| D020274 | Autoimmune Diseases of the Nervous System |
| D009422 | Nervous System Diseases |
| D014605 | Uveitis |
| D014603 | Uveal Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| D005128 | Eye Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
| D012164 | Retinal Diseases |
| D020246 | Venous Thrombosis |
| D013927 | Thrombosis |
| D016769 | Embolism and Thrombosis |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |